IKT · Inhibikase Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Sands Capital Life Sciences Pulse Fund II, L.P. 10% Owner | ▲ Buy | Open Market | 13,018,965 Shares held | 11/21/2025 | View profile |
| RA CAPITAL MANAGEMENT, L.P. Director | ▼ Sell | Other | 6,970,000 Shares held | 7/29/2026 | View profile |
| Werner Milton H. President and CEO | ▲ Buy | Open Market | 5,335,433 Shares held | 8/16/2022 | View profile |
| Bellini Roberto | ▲ Buy | Open Market | 1,460,000 Shares held | 10/21/2024 | View profile |
| Christopher Cabell President & Head of R&D | ▼ Sell | Other | 676,564 Shares held | 2/21/2026 | View profile |
| Vincent Aurentz | ▼ Sell | Other | 510,596 Shares held | 2/21/2026 | View profile |
| Kush Arvind | ▲ Buy | Open Market | 145,000 Shares held | 10/21/2024 | View profile |
| FRATTAROLI JOSEPH Chief Financial Officer | ▲ Buy | Open Market | 48,091 Shares held | 5/19/2022 | View profile |
| Amit Munshi Director | ▼ Sell | Other | 38,176 Shares held | 2/21/2026 | View profile |
| Dennis N. Berman | ▲ Buy | Option Exercise | 21,854 Shares held | 7/30/2026 | View profile |
Transaction History
| Dennis N. Berman | ▲ Buy | Option Exercise | 21,854 | $28K | 7/30/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 18,030,000 | — | 7/29/2026 |
| Vincent Aurentz | ▼ Sell | Other | 255,299 | $0 | 2/21/2026 |
| Christopher Cabell | ▼ Sell | Other | 338,282 | $0 | 2/21/2026 |
| Amit Munshi | ▼ Sell | Other | 19,089 | $0 | 2/21/2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | ▲ Buy | Open Market | 2,068,965 | $3.0M | 11/21/2025 |
| Amit Munshi | ▲ Buy | Grant | 57,265 | $0 | 2/21/2025 |
| Bellini Roberto | ▲ Buy | Open Market | 1,460,000 | $2.0M | 10/21/2024 |
| Kush Arvind | ▲ Buy | Open Market | 145,000 | $199K | 10/21/2024 |
| Amit Munshi | ▲ Buy | Open Market | 365,000 | $500K | 10/21/2024 |
| Werner Milton H. | ▲ Buy | Open Market | 5,000 | $4K | 8/16/2022 |
| Werner Milton H. | ▲ Buy | Open Market | 5,000 | $5K | 5/27/2022 |
| Werner Milton H. | ▲ Buy | Open Market | 10,000 | $6K | 5/20/2022 |
| FRATTAROLI JOSEPH | ▲ Buy | Open Market | 3,948 | $3K | 5/19/2022 |
| Werner Milton H. | ▲ Buy | Option Exercise | 21,853 | $44K | 1/3/2022 |
| Werner Milton H. | ▲ Buy | Open Market | 3,186 | $6K | 11/17/2021 |
| Werner Milton H. | ▲ Buy | Open Market | 1,334 | $3K | 11/17/2021 |
| Werner Milton H. | ▲ Buy | Open Market | 1,100 | $2K | 11/17/2021 |
| Werner Milton H. | ▲ Buy | Open Market | 17,569 | $35K | 11/17/2021 |
| Werner Milton H. | ▲ Buy | Open Market | 400 | $772 | 11/17/2021 |
| Werner Milton H. | ▲ Buy | Option Exercise | 21,853 | $44K | 8/17/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Inhibikase Announces Nasdaq Inducement Grants
Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.
Inhibikase Announces Nasdaq Inducement Grants. Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.